These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

964 related items for PubMed ID: 21958729

  • 1. Expression of HER2neu in ductal carcinoma in situ is associated with local recurrence.
    Han K, Nofech-Mozes S, Narod S, Hanna W, Vesprini D, Saskin R, Taylor C, Kong I, Paszat L, Rakovitch E.
    Clin Oncol (R Coll Radiol); 2012 Apr; 24(3):183-9. PubMed ID: 21958729
    [Abstract] [Full Text] [Related]

  • 2. The prognostic significance of multiple morphologic features and biologic markers in ductal carcinoma in situ of the breast: a study of a large cohort of patients treated with surgery alone.
    Cornfield DB, Palazzo JP, Schwartz GF, Goonewardene SA, Kovatich AJ, Chervoneva I, Hyslop T, Schwarting R.
    Cancer; 2004 Jun 01; 100(11):2317-27. PubMed ID: 15160334
    [Abstract] [Full Text] [Related]

  • 3. Improved outcomes of breast-conserving therapy for patients with ductal carcinoma in situ.
    Halasz LM, Sreedhara M, Chen YH, Bellon JR, Punglia RS, Wong JS, Harris JR, Brock JE.
    Int J Radiat Oncol Biol Phys; 2012 Mar 15; 82(4):e581-6. PubMed ID: 22208975
    [Abstract] [Full Text] [Related]

  • 4. Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy.
    Nguyen PL, Taghian AG, Katz MS, Niemierko A, Abi Raad RF, Boon WL, Bellon JR, Wong JS, Smith BL, Harris JR.
    J Clin Oncol; 2008 May 10; 26(14):2373-8. PubMed ID: 18413639
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. The expression pattern of MUC1 (EMA) is related to tumour characteristics and clinical outcome in 'pure' ductal carcinoma in situ of the breast.
    de Roos MA, van der Vegt B, Peterse JL, Patriarca C, de Vries J, de Bock GH, Wesseling J.
    Histopathology; 2007 Aug 10; 51(2):227-38. PubMed ID: 17650217
    [Abstract] [Full Text] [Related]

  • 7. Microinvasive breast cancer: ER, PR, and HER-2/neu status and clinical outcomes after breast-conserving therapy or mastectomy.
    Margalit DN, Sreedhara M, Chen YH, Catalano PJ, Nguyen PL, Golshan M, Overmoyer BA, Harris JR, Brock JE.
    Ann Surg Oncol; 2013 Mar 10; 20(3):811-8. PubMed ID: 22956068
    [Abstract] [Full Text] [Related]

  • 8. Expression of cytokeratin markers, ER-alpha, PR, HER-2/neu, and EGFR in pure ductal carcinoma in situ (DCIS) and DCIS with co-existing invasive ductal carcinoma (IDC) of the breast.
    Steinman S, Wang J, Bourne P, Yang Q, Tang P.
    Ann Clin Lab Sci; 2007 Mar 10; 37(2):127-34. PubMed ID: 17522367
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. [Clinical characteristics and survival in the operable breast cancer patients with different molecular subtypes].
    Zhang HM, Zhang BN, Xuan LX, Zhao P.
    Zhonghua Zhong Liu Za Zhi; 2009 Jun 10; 31(6):447-51. PubMed ID: 19950556
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Alterations of estrogen receptors, progesterone receptors and c-erbB2 oncogene protein expression in ductal carcinomas of the breast.
    Hussein MR, Abd-Elwahed SR, Abdulwahed AR.
    Cell Biol Int; 2008 Jun 10; 32(6):698-707. PubMed ID: 18296077
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Expression of Her2/neu, steroid receptors (ER and PR), Ki67 and p53 in invasive mammary ductal carcinoma associated with ductal carcinoma In Situ (DCIS) Versus invasive breast cancer alone.
    Mylonas I, Makovitzky J, Jeschke U, Briese V, Friese K, Gerber B.
    Anticancer Res; 2005 Jun 10; 25(3A):1719-23. PubMed ID: 16033090
    [Abstract] [Full Text] [Related]

  • 15. [Combined surgery and radiotherapy in the treatment of ductal carcinoma in situ of the breast: preliminary results of the Hungarian multicenter prospective randomised study].
    Polgár C, Orosz Z, Kahán Z, Gábor G, Jani N, Cserni G, Hadijev J, Kulka J, Sulyok Z, Boross G, Lázár G, László Z, Diczházi C, Udvarhelyi N, Szabó E, Péntek Z, Major T, Fodor J.
    Magy Onkol; 2008 Sep 10; 52(3):269-77. PubMed ID: 18845497
    [Abstract] [Full Text] [Related]

  • 16. FOXA1 expression in breast cancer--correlation with luminal subtype A and survival.
    Badve S, Turbin D, Thorat MA, Morimiya A, Nielsen TO, Perou CM, Dunn S, Huntsman DG, Nakshatri H.
    Clin Cancer Res; 2007 Aug 01; 13(15 Pt 1):4415-21. PubMed ID: 17671124
    [Abstract] [Full Text] [Related]

  • 17. Different distribution of breast cancer subtypes in breast ductal carcinoma in situ (DCIS), DCIS with microinvasion, and DCIS with invasion component.
    Yu KD, Wu LM, Liu GY, Wu J, Di GH, Shen ZZ, Shao ZM.
    Ann Surg Oncol; 2011 May 01; 18(5):1342-8. PubMed ID: 21042943
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Clinicopathologic features of ductal carcinoma in situ in young women with an emphasis on molecular subtype.
    VandenBussche CJ, Elwood H, Cimino-Mathews A, Bittar Z, Illei PB, Warzecha HN.
    Hum Pathol; 2013 Nov 01; 44(11):2487-93. PubMed ID: 24029706
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 49.